Parkinson's Disease Clinical Trial
Official title:
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical
biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD).
Development of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations
of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD
etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as
characteristics that are objectively measured and evaluated as indicators of normal
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset
of disease, and/or to mark disease progression.
Two hundred patients who have undergone neurological evaluation by their general community
neurologist and have a questionable diagnosis of PD will be recruited to participate in this
study. Subjects will be referred by the neurologists to the Institute for Neurodegenerative
Disorders (IND) in New Haven, CT.
All subjects will be clinically evaluated at IND by a two movement disorders experts. At the
baseline visit all subjects will also undergo [123I]ß-CIT SPECT ANAM, voice acoustics,
olfactory, Spiral and biochemical testing. Each movement disorders expert will make an
initial clinical diagnosis at baseline and again within three months follow-up. At the three
month visit one movement disorder expert will be provided the DAT imaging data and will
review that data with the subjects and referral physician. The other movement disorders
physician will remain blind to the imaging and all other biomarker data. The blinded
movement disorders expert will provide a final clinical diagnosis at the 12 month follow-up
visit, which will represent the 'gold standard' diagnosis in this study. Statistical
analysis to determine the sensitivity and specificity of ANAM, voice acoustics, olfactory,
Spiral and biochemical testing compared to [123I]ß-CIT SPECT, and the gold standard clinical
diagnosis will be completed. All subjects with DAT deficit and 10% of those without DAT
deficit will be asked to return for repeat evaluation at 24 months.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A |